来凯医药-B(02105)与礼来签订一项临床合作协议

智通财经2024-11-20

智通财经APP讯，来凯医药-B(02105)发布公告，集团已与礼来公司(礼来)( NYSE：LLY )签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。礼来将负责在美国执行一项I期研究并承担相关费用。集团保留LAE102的全球权益。集团致力于将这种精准治疗带给需要新型治疗选择以实现高质量体重控制的超重和肥胖症患者。据悉，LAE102是自主研发针对Act RIIA的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2484302137?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-20 12:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484302137","market":"us","top_or_hot":-1,"title":"来凯医药-B(02105)与礼来签订一项临床合作协议","media":"智通财经","content":"<div>\n<p>智通财经APP讯，来凯医药-B(02105)发布公告， 集团已与礼来公司(礼来)( NYSE：LLY )签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。礼来将负责在美国执行一项I期研究并承担相关费用。集团保留LAE102的全球权益。集团致力于将这种精准治疗带给需要新型治疗选择以实现高质量体重控制的超重和肥胖症患者。据悉，LAE102是自主研发针对Act RIIA的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1213300.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>来凯医药-B(02105)与礼来签订一项临床合作协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n来凯医药-B(02105)与礼来签订一项临床合作协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 12:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1213300.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，来凯医药-B(02105)发布公告， 集团已与礼来公司(礼来)( NYSE：LLY )签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。礼来将负责在美国执行一项I期研究并承担相关费用。集团保留LAE102的全球权益。集团致力于将这种精准治疗带给需要新型治疗选择以实现高质量体重控制的超重和肥胖症患者。据悉，LAE102是自主研发针对Act RIIA的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1213300.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014880.SGD","symbol_name":"大华全球优质成长基金Acc SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1213300.html","article_id":"2484302137","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484302137","pubTimestamp":1732076241,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，来凯医药-B 发布公告， 集团已与礼来公司(礼来)签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。礼来将负责在美国执行一项I期研究并承担相关费用。集团保留LAE102的全球权益。据悉，LAE102是自主研发针对Act RIIA的单克隆抗体，Act RIIA是在肌肉再生和脂肪代谢中发挥重要作用的受体。LAE102与GLP -1受体激动剂联用可进一步减少脂肪并显著降低GLP -1受体激动剂导致的肌肉流失，使LAE102成为一种高质量体重控制候选药物。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","BK4007":"制药","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2063271972.USD":"富兰克林创新领域基金","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","SG9999001176.USD":"United Global Healthcare Acc USD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LLY":"礼来","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD"},"translate_title":"Laikai Medicine-B (02105) signed a clinical cooperation agreement with Eli Lilly","themeId":"07e0b9a8029060879506d5b591f8f763","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"智通财经APP讯，来凯医药-B(02105)发布公告， 集团已与礼来公司(礼来)( NYSE：LLY )签订一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。礼来将负责在美国执行一项I期研究并承担相关费用。集团保留LAE102的全球权益。集团致力于将这种精准治疗带给需要新型治疗选择以实现高质量体重控制的超重和肥胖症患者。据悉，LAE102是自主研发针对Act RIIA的单克隆抗体，Act RIIA是在肌肉再生和脂肪代谢中发挥重要作用的受体。在临床前模型中，LAE102已显示出增加肌肉并减少脂肪的效果。LAE102与GLP -1受体激动剂联用可进一步减少脂肪并显著降低GLP -1受体激动剂导致的肌肉流失，使LAE102成为一种高质量体重控制候选药物。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484302137","isCrawlerRequest":true}